 | | Vol. 13.06 – 21 February, 2024 |
| |
|
|
| Scientists identified a subset of vascular pericytes that promoted tumorigenesis and tyrosine kinase inhibitors resistance by functioning as the primary methionine source for CSCs in clear cell renal cell carcinoma.
[Cell Metabolism] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using a stem cell-based phenotypic drug-screening pipeline, the authors identified the dopamine transporter antagonist vanoxerine, a compound with previously demonstrated clinical safety, as a cancer-specific downregulator of G9a expression.
[Nature Cancer] |
|
|
|
| The multiomics screening revealed that OTUD1 protein played an important role in retaining ovarian CSC properties. Mechanistically, the elevated OTUD1 protein levels led to the formation of OTUD1-based cytoplasmic aggresomes
[Nature Communications] |
|
|
|
| Researchers unveiled a cellular differentiation hierarchy within acute promyelocytic leukemia blasts, rooted in leukemic stem-like cells.
[Nature Communications] |
|
|
|
| The authors demonstrated that methyltransferase-like 3 was highly expressed in CD44(+) cells and promoted CSCs phenotype. Using RNA-sequencing analysis, they showed that Spalt-like transcription factor 4 (SALL4) was involved in the maintenance of CSCs properties.
[Cell Death & Disease] |
|
|
|
| Scientists showed that overexpression of fructose-1,6-bisphosphatase 1 (FBP1), a gluconeogenic enzyme, functions as a tumor suppressor to regulate the stemness of NSC led to a decrease in the proportion of CD133-positive cells, weakened tumorigenicity, and decreased expression of stemness factors.
[Cellular And Molecular Life Sciences] |
|
|
|
| The effect of CSCs on CAR-T cell therapy was determined using in vitro and in vivo assays. Subsequently, Interleukin-24 (IL-24) was expressed along with CAR in T cells.
[British Journal Of Cancer] |
|
|
|
| A series of novel N-(anthracen-9-ylmethyl) benzamide derivatives against ZNF207 were rationally designed and synthesized. The inhibitory activity was evaluated, and their structure–activity relationships were summarized.
[Journal Of Medicinal Chemistry] |
|
|
|
| Researchers used pharmacological inhibitor of H3K4, knockdown of KMT2B or KMT2D in breast cancer cells, real time PCR, response to chemotherapy, flow cytometry, and more for circulating markers of CSCs and DNA hydroxylases in breast cancer patients.
[Cell Communication and Signaling] |
|  |
|
|
|
| Circulating tumor cells exhibit molecular diversity and stem-like and mesenchymal features, even when derived from primary tumor tissue from a single patient.
[Stem Cell Reviews And Reports] |
|
|
|
|
| The National Institutes of Health (NIH) has launched a clinical trials network to evaluate emerging technologies for cancer screening.
[National Institutes of Health] |
|
|
|
| Iovance Biotherapeutics, Inc. announced that the US FDA has approved AMTAGVI™ suspension for intravenous infusion.
[Iovance Biotherapeutics, Inc.] |
|
|
|
|
| April 4 – 5, 2024
Cincinnati, Ohio, United States |
|
|
|
|
|
| | University of Southern California – Los Angeles, California, United States |
|
|
|
| | UC Davis – Davis, California, United States |
|
|
|
| | Cyprus Cancer Research Institute – Aglandjia, Cyprus |
|
|
|
| | The Genomics Research Center, Academia Sinica – Taipei City, Taiwan |
|
|
|
| | University of Washington – Seattle, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
